-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
-The new PD-L1/4-1BB bispecific antibody ATG-101 has shown anti-tumor activity in preclinical models of immune checkpoint inhibitor resistance or recurrence and can effectively avoid liver toxicity.
At the same time, it is further analyzed by quantitative system pharmacological model Supported the dose selection strategy for the drug
-Preclinical data of ERK1/2 inhibitor ATG-017 combination therapy supports future clinical development
Shanghai and Hong Kong November 15, 2021/PRNewswire/ - Deqi Pharmaceutical Co.
, Ltd.
(abbreviated as a leading innovative biopharmaceutical company dedicated to the development and commercialization of the first and/or best-in-class blood and solid tumor therapies of its kind "Deqi Pharmaceutical", Hong Kong Stock Exchange stock code: 6996.
HK) announced today that the company announced experimental data from three studies in the form of a poster at the annual meeting of the Society for Tumor Immunotherapy (SITC) in Washington (https: //
.
Dr.
Mei Jianming, Founder, Chairman and CEO of Deqi Pharmaceuticals, said: “We are honored to have the opportunity to present two ATG-101 and ATGs from two phase I clinical studies during the SITC annual meeting on November 12, 2021.
-017 Pre-clinical data
.
The unique mechanism and good safety and anti-tumor activity of these two new drugs fully demonstrate the company's fruitful efforts in realizing the mission of developing the first and/or best-in-class drugs
Poster summary
Poster #893: ATG-101 is active in "cold" tumors and does not show hepatotoxicity in preclinical models
As a new PD-L1/4-1BB bispecific antibody, ATG-101 can simultaneously activate tumor-infiltrating lymphocytes and inhibit immune checkpoints, and avoid inducing liver toxicity
.
The data released by Deqi Pharmaceutical this time comes from a series of in vivo and in vitro studies.
The data presented in this poster shows that ATG-101 still maintains excellent efficacy in tumor models that are resistant to anti-PD-L1 drugs or relapse after treatment
.
In addition, ATG-101 enhances the activation of T cells and exhausted T cells under PD-L1 cross-linking conditions, and realizes the transformation of tumors from "cold" to "hot"
Poster #608: ATG-017 combined with immune checkpoint inhibitors shows synergistic effects in an in vivo model, and the data supports the clinical development of this combination therapy
ATG-017 is a potent and selective small molecule inhibitor that acts on extracellular signal-regulated kinase 1 and 2 (ERK1/2)
.
The data released by Deqi Pharmaceutical this time comes from an in vivo study that evaluated the combination of ATG-017 and anti-PD-L1 monoclonal antibody (atezizumab) in a small malignant tumor that is resistant to immune checkpoint inhibitors.
The poster data showed that the combination therapy enhanced anti-tumor activity and brought about the percentage of tumor infiltrating CD8+ T cells and NK cells in the tumor microenvironment, as well as the ratio of CD8:CD4 T cells and the M1:M2 subtype of macrophages.
In order to realize the transformation of the tumor from “cold” to “hot”
.
This result proves that ATG-017 and immune checkpoint inhibitors have a potential synergistic effect, which provides the next step for the clinical research of the combination therapy for the treatment of a variety of solid tumors including solid tumors resistant to immune checkpoint inhibitors.
Poster #227: Calculation and analysis tools help the selection of dosage for ATG-101 clinical trials
The bispecific antibody ATG-101 can form a trimer (combined from ATG-101 with cells expressing PD-L1 and 4-1BB) to activate tumor infiltrating lymphocytes and suppress immune checkpoints
.
The measurement of trimeric complexes is essential to determine the best dosage for clinical studies, but this is difficult to accomplish in clinical trials
In the poster, Deqi Pharmaceutical and its partner Applied BioMath reported a development project of a computational semi-mechanical pharmacology model that can be used to determine the dosage of ATG-101 in clinical trials
.
The model simulates the inhibition of tumor growth in vivo to predict the formation of trimers, free drug levels, and receptor occupancy over time
These abstracts have been officially released on the SITC official website, and their details are as follows:
Abstract Number: 227
Title: Computational semi-mechanical pharmacology model of PD-L1/4-1BB bispecific antibody ATG-101 for the treatment of solid tumors and non-Hodgkin’s lymphoma (NHL)
Exhibition time: November 12-14, 2021, 7:00-17:00 (US Eastern Time)
Speaker: David C.
Flowers, Applied BioMath, LLC
First author: David C.
Flowers, Applied BioMath, LLC
Abstract Number: 608
Title: Synergy of ATG-017 (ERK1/2 Inhibitor) and Immune Checkpoint Inhibitors in Preclinical Cancer Models
Exhibition time: November 12-14, 2021, 7:00-17:00 (US Eastern Time)
Speaker: Dr.
Hou Bing, Deqi Pharmaceutical
First author: Dr.
Chen Peng, Deqi Pharmaceutical
Abstract Number: 893
Title: As a new PD-L1/4-1BB bispecific antibody, ATG-101 enhances anti-tumor immunity through immune checkpoint suppression and PDL1-directed 4-1BB activation
Exhibition time: November 12-14, 2021, 7:00-17:00 (US Eastern Time)
Speaker: Dr.
Hou Bing, Deqi Pharmaceutical
First author: Dr.
Wenhui Yu, Deqi Pharmaceutical
About ATG-101
ATG-101 is a new PD-L1/4-1BB bispecific antibody that is being developed for the treatment of metastatic/advanced solid tumors and B-cell non-Hodgkin’s lymphoma (B-NHL)
.
ATG-101 can simultaneously block PD-L1/PD-1 binding and activate 4-1BB costimulatory signals, thereby activating anti-tumor immune effector cells
About ATG-017
ATG-017 is a potent and selective small molecule inhibitor that acts on extracellular signal-regulated kinase 1 and 2 (ERK1/2)
.
ERK1/2 is a type of serine/threonine protein kinase, which acts as the terminal kinase of the RAS-MAPK signal transduction cascade
.
This cascade pathway regulates various cellular processes such as cell proliferation
.
The RAS-MAPK pathway dysregulation occurs in more than 30% of cancer patients, and the most common change is RAS or BRAF gene mutations in multiple tumor types
.
ERK inhibitors can target both RAS and BRAF mutant diseases
.
In non-clinical pharmacology studies, ATG-017 has shown strong inhibitory effects on ERK1/2 enzyme activity and tumor growth in vitro and in vivo
.
Currently, Deqi Pharmaceuticals is carrying out a phase I dose-climbing test of ATG-017 for the treatment of advanced solid tumors and hematological malignancies in Australia
.
About Deqi Pharmaceutical's R&D Day Activities
Deck Pharmaceuticals will invite its founder/chairman/CEO Dr.
Mei Jianming, Chief Commercial Officer Mr.
John Chin, Chief Medical Officer Dr.
Kevin Lynch, Chief Scientific Officer Dr.
Shan Bo and more core members of the management team on the R&D Day In-depth introduction to the company's R&D projects
.
The conference will be held on November 16th and November 18th, 2021, in online English and offline Chinese respectively.
At that time, the investor calendar module on the official website of Deqi Pharmaceuticals will broadcast the above speeches online
.
Welcome to register in advance and participate in the conference:
R&D Japanese and English Sessions-Online Conference
Date: Tuesday, November 16, 2021 Time: 8:30 am to 11:30 am EST / 9:30 pm to 12:30 am Beijing time Registration link: https:// pfrKl2
Chinese R&D Day Sessions-Webcast of Offline Conferences
Date: Thursday, November 18, 2021 Time: 1:30 pm to 5:30 pm Beijing time Registration link: https:// Deqi Pharmaceutical
Deqi Pharmaceutical Co.
, Ltd.
(abbreviated as "Deqi Pharmaceutical", Hong Kong Stock Exchange stock code: 6996.
HK) is a leading R&D-driven biopharmaceutical company dedicated to providing the most advanced therapies and treatments for patients in Asia Pacific and even the world Tumors and other life-threatening diseases
.
Since its official operation in 2017, Deqi Pharmaceuticals has established a rich product pipeline that extends from pre-clinical to clinical stages through cooperative introduction and independent research and development
.
At present, Deqi Pharmaceutical has 13 products under development, of which 5 products have Asia-Pacific rights including the Greater China market, and 8 products have global rights
.
Deck Pharma has obtained 18 clinical approval documents (IND) in multiple Asia-Pacific markets, and submitted 6 new drug listing applications (NDA), of which Celiniso has been approved for new drug marketing in South Korea
.
With the vision of "Doctors have no boundaries, innovation and sustainability", Deqi Pharmaceuticals will focus on the early R&D, clinical research, drug production and commercialization of the first and best-in-class therapies to solve urgent clinical needs
.
Forward-looking statements
The forward-looking statements made in this article only relate to events or information as of the date when the statement is made in this article
.
Except as required by law, we have no obligation to update or publicly revise any forward-looking statements and unexpected events after the date of forward-looking statements, regardless of whether new information, future events or other circumstances appear
.
Please read this article carefully and understand that our actual future results or performance may differ materially from expectations
.
Statements or references in this article regarding the intentions of any directors or the company were made on the date of publication of this article
.
Any such intentions may change due to future development
.
For further discussion of these factors and other factors that may cause future performance to differ materially from any forward-looking statements, please refer to the section entitled "Risk Factors" in our periodic report to the Hong Kong Stock Exchange and our period as of December 2020.
Other risks and uncertainties described in the company’s annual report on the 31st, and subsequent documents submitted to the Hong Kong Stock Exchange
.
Source: Deqi Pharmaceutical Co.
, Ltd.
